Drug
Ocrelizumab
Ocrelizumab: highest development phase Phase 3, developed by Roche. 2 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Roche
Trials
| Drug | Phase | Indication |
|---|---|---|
| Ocrelizumab NCT04544436 | Phase 3 | Multiple Sclerosis |
| Ocrelizumab NCT04075266 | Phase 2 | Multiple Sclerosis |
Latest
Follow Ocrelizumab on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.